The introduction of dinoprost tromethamine (Prostin F2 Alpha) as an abortifacient in the second trimester of pregnancy represents the first clinical use of a prostaglandin. Various synthetic analogues of the naturally occurring derivatives are being employed investigationally in the treatment of peptic ulcer, hypertension, asthma, and hypercalcemia. In the United States, dinoprost tromethamine is primarily administered intra-amniotically. Despite the fact that a substantial number of patients experience allergic reactions, hypertension, bronchospasm, nausea, vomiting, cramps, and diarrhea, the efficacy and relative safety of dinoprost tromethamine establish it as superior to intra-amniotic instillation of hypertonic saline. Cervical laceration, laceration or rupture of the lower uterine segment, retention of the placenta, and hemorrhage in part reflect the intensity of uterine contraction induced by dinoprost. Experience in administration improves the therapeutic response and diminishes adverse reactions.
将氨丁三醇地诺前列素（前列腺素F2α）作为妊娠中期堕胎药引入，代表了前列腺素的首次临床应用。天然存在的衍生物的各种合成类似物正用于消化性溃疡、高血压、哮喘和高钙血症的治疗研究。在美国，氨丁三醇地诺前列素主要通过羊膜腔内给药。尽管大量患者会出现过敏反应、高血压、支气管痉挛、恶心、呕吐、痉挛和腹泻，但氨丁三醇地诺前列素的疗效和相对安全性使其优于羊膜腔内注入高渗盐水。宫颈撕裂、子宫下段撕裂或破裂、胎盘残留和出血部分反映了氨丁三醇引起的子宫收缩强度。给药经验可改善治疗反应并减少不良反应。
